UNSPSC 51172307: Trientine

This classification denotes a metal chelator with the molecular formula C6H18N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SJ76Y07H5F, chemically known as 1,4,7,10-tetraazadecane but generally known as trientine, which bears US NIH Compound Identifier 5565. European Medicines Agency schedules Trientine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11281MIG. The term TRIENTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20).

UNSPSC 51172307 Trientine is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement activity. The single recent opportunity in the dataset — Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services — is plainly unrelated to trientine, a pharmaceutical compound used in copper chelation therapy. The solicitation encompasses staffing two collection sites in Plano and McKinney, operating an Interactive Voice Response system for randomized testing notifications, conducting immunoassay screening with LC/MS/MS or GC/MS confirmation, and offering alternative testing methodologies including oral fluid and hair testing. The vendor must maintain lab certification from SAMHSA, TX DPS, or CAP and submit pricing on a per-test basis with three service models: screening only, confirmation after screening, and screening with automatic confirmation of positives. No other issuing bodies appear in the recent-opportunities block.

Collin County's RFP 2026-327 was posted on September 25, 2026, with a response due date of July 23, 2026 (a discrepancy in the source), and an anticipated award date of August 10, 2026. The estimated contract value is $600,000 over a two-year initial term with three optional one-year renewal periods not to exceed five years total. Annual testing demand is approximately 25,031 tests, comprising 5,452 five-panel screens, 18,006 six-panel screens, and ancillary testing. Evaluation comprises compliance review and Phase 1 detailed proposal assessment (vendor understanding, firm qualifications, client references, and cost), with optional Phase 2 demonstrations and interviews worth up to 30 points. Funding derives from Texas Department of Criminal Justice-Community Justice Assistance Division appropriations, subject to annual availability. The code shows little relevant recent activity under its nominal pharmaceutical scope.